Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Liangxing Wu

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Plos One|June 12, 2013
High-contrast fluorescence imaging in fixed and living cells using optimized optical switchesLiangxing Wu, Yingrui Dai, Xiaoli Jiang, et al.
Bioorganic & Medicinal Chemistry Letters|November 15, 2021
Inhibition of ALK2 with bicyclic pyridyllactamsMichael R Witten, Liangxing Wu, Cheng-Tsung Lai, et al.
Organic & Biomolecular Chemistry|April 2, 2011
Energy transfer cassettes in silica nanoparticles target intracellular organellesJiney Jose, Aurore Loudet, Yuichiro Ueno, et al.
ACS Medicinal Chemistry Letters|November 17, 2022
Discovery of 5,7-Dihydro-6<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-6-ones as Highly Selective CDK2 InhibitorsAlexander Sokolsky, Sarah Winterton, Keith Kennedy, et al.
ACS Medicinal Chemistry Letters|July 21, 2022
Discovery of Novel Pyrazolopyrimidines as Potent, Selective, and Orally Bioavailable Inhibitors of ALK2Minh H Nguyen, Onur Atasoylu, Liangxing Wu, et al.
Journal of Medicinal Chemistry|July 16, 2021
Discovery of Pemigatinib: A Potent and Selective Fibroblast Growth Factor Receptor (FGFR) InhibitorLiangxing Wu, Colin Zhang, Chunhong He, et al.
Plos One|April 22, 2020
INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor modelsPhillip C C Liu, Holly Koblish, Liangxing Wu, et al.
Journal of Medicinal Chemistry|February 7, 2024
Discovery of (4-Pyrazolyl)-2-aminopyrimidines as Potent and Selective Inhibitors of Cyclin-Dependent Kinase 2Joshua R Hummel, Kai-Jiong Xiao, Jeffrey C Yang, et al.
Cancer Discovery|March 7, 2022
Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 InhibitorHolly K Koblish, Liangxing Wu, Liang-Chuan S Wang, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Plos One|June 12, 2013
High-contrast fluorescence imaging in fixed and living cells using optimized optical switchesLiangxing Wu, Yingrui Dai, Xiaoli Jiang, et al.
Bioorganic & Medicinal Chemistry Letters|November 15, 2021
Inhibition of ALK2 with bicyclic pyridyllactamsMichael R Witten, Liangxing Wu, Cheng-Tsung Lai, et al.
Organic & Biomolecular Chemistry|April 2, 2011
Energy transfer cassettes in silica nanoparticles target intracellular organellesJiney Jose, Aurore Loudet, Yuichiro Ueno, et al.
ACS Medicinal Chemistry Letters|November 17, 2022
Discovery of 5,7-Dihydro-6<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-6-ones as Highly Selective CDK2 InhibitorsAlexander Sokolsky, Sarah Winterton, Keith Kennedy, et al.
ACS Medicinal Chemistry Letters|July 21, 2022
Discovery of Novel Pyrazolopyrimidines as Potent, Selective, and Orally Bioavailable Inhibitors of ALK2Minh H Nguyen, Onur Atasoylu, Liangxing Wu, et al.
Journal of Medicinal Chemistry|July 16, 2021
Discovery of Pemigatinib: A Potent and Selective Fibroblast Growth Factor Receptor (FGFR) InhibitorLiangxing Wu, Colin Zhang, Chunhong He, et al.
Plos One|April 22, 2020
INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor modelsPhillip C C Liu, Holly Koblish, Liangxing Wu, et al.
Journal of Medicinal Chemistry|February 7, 2024
Discovery of (4-Pyrazolyl)-2-aminopyrimidines as Potent and Selective Inhibitors of Cyclin-Dependent Kinase 2Joshua R Hummel, Kai-Jiong Xiao, Jeffrey C Yang, et al.
Cancer Discovery|March 7, 2022
Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 InhibitorHolly K Koblish, Liangxing Wu, Liang-Chuan S Wang, et al.
Pageof 2